Phd in MOLECULAR MEDICINE

email: giuseppe.giannini@uniroma1.it
phone: 063058757
building: RM110b
room: 212

SHORT CURRICULUM VITAE

PRESENT POSITION
Full Professor, General Pathology, MED/04

DEPT. OF MOLECULAR MEDICINE

ADDITIONAL APPOINTMENTS
- Head, Research Unit “Cancer Molecular Genetics”, Dept. Molecular Medicine, University La Sapienza
- Head, Unità Programma (UP) - UOC equivalente di Diagnostica Molecolare Avanzata in Oncologia e Responsabile facente funzione dell’Unità Operativa Semplice Dipartimentale (UOSD) di Oncologia Molecolare, DAI di Medicina Diagnostica e Radiologia, Policlinico Umberto I, Facoltà di Farmacia e Medicina, Università di Roma La Sapienza.

EDUCATION AND CAREER
2011- today: Full Professor, General Pathology (SSD Med04), Dept. Molecular Medicine, University La Sapienza.
2001 – 2011: Associate Professor, General Pathology (SSD Med04), Dept. Experimental Medicine, University La Sapienza
1998 – 2001: Assistant Professor, General Pathology, Dept. Experimental Medicine, University La Sapienza.
1996 – 1997: Visiting Scientist, Cellular and Molecular Biology Section, NCI, NIH, Bethesda Maryland, USA.
1993 – 1997: Post-Graduate Specialty School, University Of L’Aquila, Faculty Of Medicine, L’Aquila, Italy. Graduation Cum Laude, Oncology.
1990 – 1993: Post-Doctoral Fellow, Lennart Philipson Director’s Group, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
1989 – 1990: Scientist, Molecular Genetics Laboratory, Raggio Italgene, Spa, Pomezia (Rm) Italy
1987 – 1990: Post-Graduate Specialty School, University La Sapienza, Faculty Of Medicine, Rome, Italy, Graduation Cum Laude, Allergy.
1981 – 1987: Degree in Medicine And Surgery, University La Sapienza, Faculty Of Medicine, Rome, Italy. Graduation Cum Laude.

MOST RELEVANT RESEARCH LINES
1. Development and cancer (medulloblastoma) in the cerebellum: crossroads between replication stress, the DNA Damage Response and the Sonic Hedgehog pathway;
2. The Nijmegen Breakage Syndrome and the MRN complex;
3. Molecular targets and mechanisms of MYCN-driven tumor development (neuroblastoma);
4. Hereditary Breast cancer: BRCA1 and BRCA2 genes and beyond;
5. Molecular biomarkers and target therapy for cancer.

FIVE SELECTED PUBLICATIONS
1. Petroni M, Fabretti F, Di Giulio S, Nicolis Di Robilant V, La Monica V, Moretti M, Belardinilli F, Bufalieri F, Coppa A, Paci P, Corsi A, De Smaele E, Coni S, Canettieri G, Di Marcotullio L, Wang ZQ, Giannini G. A gene dosage-dependent effect unveils NBS1 as both a haploinsufficient tumour suppressor and an essential gene for SHH-medulloblastoma. Neuropathology and Appl Neurobiology. 2022 Oct;48(6):e12837. doi: 10.1111/nan.12837.
2. Sibilio P, Belardinilli F, Licursi V, Paci P, Giannini G. An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy. Biology Direct. 2022 May 9;17(1):10. doi: 10.1186/s13062-022-00324-y.
3. Di Giulio S, Colicchia V, Pastorino F, Pedretti F, Fabretti F, Nicolis Di Robilant V, Ramponi V, Scafetta G, Moretti M, Licursi V, Belardinilli F, Peruzzi G, Infante P, Goffredo B, Coppa A, Canettieri G, Bartolazzi A, Ponzoni M, Giannini G, Petroni M. A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors. Oncogene. 2021 Oncogene. 2021 Oct;40(43):6143-6152. doi: 10.1038/s41388-021-02003-0.
4. Nicolazzo C, Belardinilli F, Vestri A, Magri V, De Renzi G, De Meo M, Caponnetto S, Di Nicolantonio F, Cortesi E, *Giannini G, *Gazzaniga P. RAS Mutation Conversion in Bevacizumab-Treated Metastatic Colorectal Cancer Patients: A Liquid Biopsy Based Study. Cancers (Basel). 2022 Feb 4;14(3):802. doi: 10.3390/cancers14030802. (*co-senior author).
5. Patel VL, Busch EL, Friebel TM, Cronin A, […], Giannini G, […], Neuhausen SL, Ottini L, Nielsen HR, Rebbeck TR. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research. 2020 Feb 1;80(3):624-638. doi: 10.1158/0008-5472.CAN-19-1840.